GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » YoY EBITDA Growth

Virax Biolabs Group (Virax Biolabs Group) YoY EBITDA Growth : -337.83% (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Virax Biolabs Group's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was -337.83%.

Virax Biolabs Group's EBITDA per Share for the six months ended in Sep. 2023 was $-16.21.

Virax Biolabs Group YoY EBITDA Growth Historical Data

The historical data trend for Virax Biolabs Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group YoY EBITDA Growth Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
YoY EBITDA Growth
- 0.88 -169.43 -67.87

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
YoY EBITDA Growth Get a 7-Day Free Trial -51.23 -330.42 -651.12 -148.89 -337.83

Virax Biolabs Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Virax Biolabs Group's YoY EBITDA Growth for the fiscal year that ended in Mar. 2023 is calculated as:

YoY EBITDA Growth (A: Mar. 2023 )
=(EBITDA per Share (A: Mar. 2023 )-EBITDA per Share (A: Mar. 2022 ))/ | EBITDA per Share (A: Mar. 2022 ) |
=(-2.56--1.525)/ | -1.525 |
=-67.87 %

Virax Biolabs Group's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (Q: Sep. 2023 )
=(EBITDA per Share (Q: Sep. 2023 )-EBITDA per Share (Q: Sep. 2022 )) / | EBITDA per Share (Q: Sep. 2022 )) |
=(-16.213--3.703)/ | -3.703 |
=-337.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » YoY EBITDA Growth
Comparable Companies
SILO IKT TENX XBIO KPRX HOTH ABVC APTX TSOI ZIVO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Website
https://www.viraxbiolabs.com
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.